Anti-angiogenic agents

• US 6,271,220 B1
• Filed: 09/03/1999
• Issued: 08/07/2001
• Est. Priority Date: 03/11/1998
• Status: Expired due to Fees

• Current Assignee: Allergan Incorporated (Abbvie Incorporated), Corning Incorporated
• Original Assignee: Allergan Sales LLC (Abbvie Incorporated)
• Inventors: Garst, Michael E., MacDonald, Timothy L.
• Primary Examiner(s): McKane, Joseph K.
• Assistant Examiner(s): MURRAY, JOSEPH H
• Application Number:
  US09/380,866
• Time in Patent Office: 704 Days
• Field of Search: 514/177, 514/178, 514/179, 514/182, 552/558, 552/614, 552/617, 552/625, 552/627
• US Class Current: 514/177
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: C07J 1/00 Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
• CPC Class Codes: C07J 5/00 Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
• CPC Class Codes: C07J 7/00 Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms C07J5/00 takes precedence

Abstract

The application discloses methods of treating mammalian diseases characterized by undesirable angiogenesis by administering compounds including those having the general formulae

wherein A is a fused tropone having a general formula:

wherein X is selected from the group consisting of hydrogen, hydroxy, carboxy, halogen, nitro, C₁ to C₁₂ alkenyl, C₁ to C₁₂ alkyl, C₁ to C₁₂ alkoxy, SR, NR₂, OSO₃⁻, OSO₂NR₂, HNSO₃⁻, NHSO₂NR₂, SSO₃⁻, SSO₂NR₂, wherein R is hydrogen or a C₁ to C₆ alkyl and the 17-ester and keto derivatives thereof, in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the method of the invention.

Claims

1. A method for treating a mammalian disease characterized by undesirable angiogenesis, said method comprising administering to a mammal having said undesirable angiogenesis a compound of the formula below, said compound being administered in an amount sufficient to inhibit angiogenesis:

wherein A is a fused tropone having a general formula;

wherein X is selected from the group consisting of H, Cl, Br, methoxy and ethoxy.

2. A compound for treating a mammalian disease characterized by undesirable angiogenesis, of the formula below:

wherein A is a fused tropone having a general formula;

wherein X is selected from the group consisting of H, Cl, Br, methoxy and ethoxy.

3. A method for treating a mammalian disease characterized by undesirable angiogenesis, said method comprising administering to a mammal having said undesirable angiogenesis, a compound of the formula below, said compound being administered in an amount sufficient to inhibit angiogenesis:

wherein A is

and X is selected from the group consisting of chloro and bromo.

4. A method for treating a mammalian disease characterized by undesirable angiogenesis, said method comprising administering to a mammal having said undesirable angiogenesis, a compound of the formula below, said compound being administered in an amount sufficient to inhibit angiogenesis:

wherein A is

and X is methoxy.

5. A compound for treating a mammalian disease characterized by undesirable angiogenesis, of the formula below:

wherein A is

and X is selected from the group consisting of chloro and bromo.

6. A compound for treating a mammalian disease characterized by undesirable angiogenesis, of the formula below

wherein A is

and X is methoxy.